# Venlafaxine

## Efexor XR 75mg

| 藥物代碼 | OEFE7 |
| :--- | :--- |
| 適應症 | Major depressive disorder; generalized anxiety disorder; social anxiety disorder; panic disorder. |
| 副作用 | Dizziness, sedation, dry mouth, insomnia, nervousness, tremor, somnolence, anorexia, constipation, nausea, vomiting, abnormal ejaculation/orgasm \(males\), erectile dysfunction, urinary hesitancy, sweating, asthenia, hypertension, hot flushes, ecchymosis, mucous membrane bleeding, thrombocytopenia, hypercholesterolaemia, yawning, fatigue, nausea, appetite & weight loss, decreased libido, sweating, anorexia, visual disturbances.Cardiovascular: Hypertension \(3% to 13%\)Dermatologic: Sweating symptom \(6.7% to 25% \)Endocrine metabolic: Weight loss \(3% to 47% \)Gastrointestinal: Constipation \(8% to 15% \), Loss of appetite \(8% to 22% \), Nausea \(21% to 58% \), Xerostomia \(12% to 22% \)Neurologic: Asthenia \(8% to 19% \), Dizziness \(11% to 23.9% \), Dream disorder \(3% to 7% \), Headache \(25% to 38% \), Insomnia \(14% to 24% \), Somnolence \(14% to 26% \), Tremor \(1.1% to 10.2% \)Ophthalmic: Blurred vision \(4% to 6% \)Psychiatric: Feeling nervous \(4% to 21.3% \)Reproductive: Abnormal ejaculation \(2.2% to 19% \), Impotence \(2.1% to 6% \), Orgasm disorder \(2% to 5% \) |
| 禁忌 | Concomitant or within 14 days of MAOIs. Efexor XR must be discontinued for at least 7 days before starting treatment with MAOI. Severe renal or hepatic impairment. Pregnancy & lactation. Children &lt; 18 years. |
| 藥物保存方式 | 室溫 |
| 用法用量 | Should be taken with food \(XR cap: Swallow whole, do not chew/crush.\). 75 mg once daily. After 2 weeks, the dose may be increased to 150 mg once daily & further to 225 mg once daily if needed. |
| 肝功能異常 | 需 調 整 劑 量  中度肝障礙病患，應以減半用量開始治療 因個別肝硬化患者之差異性大，可能需要個別調整用量 |
| 腎功能異常 | 需 調 整 劑 量 |
| 懷孕用藥危分級 | 除非治療上需要 |
| 孕期用藥建議 | Human data suggest risk in 3rd trimester |
| 附帶說明 | N/A |
| 哺乳期用藥建議 | No \(Limited\) Human Data - Potential Toxicity 無\(很少\)資料 - 避免使用 |
| 附帶說明 | N/A |
| 注射劑給藥建議途徑 | N/A |
| 乾粉稀釋液 | N/A |
| 輸注點滴液 | N/A |
| IVP 用法建議 | N/A |
| IVD 用法建議 | N/A |
| 注意事項 | N/A |

## Faxine 37.5mg

| 藥物代碼 | OFAX |
| :--- | :--- |
| 適應症 | Treatment of depression, including melancholia. |
| 副作用 | Dizziness, sedation, dry mouth, insomnia, nervousness, tremor, somnolence, anorexia, constipation, nausea, vomiting, abnormal ejaculation/orgasm \(males\), erectile dysfunction, urinary hesitancy, sweating, asthenia, hypertension, hot flushes, ecchymosis, mucus membrane bleeding, thrombocytopenia, hypercholesterolemia, yawning, fatigue, nausea, appetite & wt loss, decreased libido, sweating, anorexia, visual disturbancesCardiovascular: Hypertension \(3% to 13%\)Dermatologic: Sweating symptom \(6.7% to 25% \)Endocrine metabolic: Weight loss \(3% to 47% \)Gastrointestinal: Constipation \(8% to 15% \), Loss of appetite \(8% to 22% \), Nausea \(21% to 58% \), Xerostomia \(12% to 22% \)Neurologic: Asthenia \(8% to 19% \), Dizziness \(11% to 23.9% \), Dream disorder \(3% to 7% \), Headache \(25% to 38% \), Insomnia \(14% to 24% \), Somnolence \(14% to 26% \), Tremor \(1.1% to 10.2% \)Ophthalmic: Blurred vision \(4% to 6% \)Psychiatric: Feeling nervous \(4% to 21.3% \)Reproductive: Abnormal ejaculation \(2.2% to 19% \), Impotence \(2.1% to 6% \), Orgasm disorder \(2% to 5% \) |
| 禁忌 | Coadministration with MAOIs. |
| 藥物保存方式 | 室溫 |
| 用法用量 | Adult Initially 75 mg/day in 2-3 divided doses, can be increased in increments of up to 75 mg/day at intervals of ≧ 4 days. Dose can be titrated up to 225 mg/day in moderate depression & 375 mg/day for severe depression |
| 肝功能異常 | 需 調 整 劑 量  輕度或中度肝功能不全病患建議降低 usual dosage by 50% or more |
| 腎功能異常 | 需 調 整 劑 量 |
| 懷孕用藥危分級 | 除非治療上需要 |
| 孕期用藥建議 | Human data suggest risk in 3rd trimester |
| 附帶說明 | N/A |
| 哺乳期用藥建議 | No \(Limited\) Human Data - Potential Toxicity 無\(很少\)資料 - 避免使用 |
| 附帶說明 | N/A |
| 注射劑給藥建議途徑 | N/A |
| 乾粉稀釋液 | N/A |
| 輸注點滴液 | N/A |
| IVP 用法建議 | N/A |
| IVD 用法建議 | N/A |
| 注意事項 | N/A |

